ClinicalTrials.gg
Sign In

RNA Virus Infections clinical trials

The registry lists 98 studies for RNA Virus Infections across more than 10 countries. 7 are recruiting or about to start. 6 of them are mainly about RNA Virus Infections (how this is decided). Per ClinicalTrials.gov, last updated 2026-10-15. Counting its 47 narrower conditions too, such as COVID-19: 22,090 studies, 1,656 open.

Get an email when these change. Save the RNA Virus Infections studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Watch these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your saved searches, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your saved searches. Stop any time.

Status

Completed
71
Terminated
8
Status unknown
7
Recruiting
5
Active, not recruiting
4
Enrolling by invitation
1

Phase

Phase 3
31
Phase 2
28
Phase 1
21
Phase 4
5

Where

United States
52
Canada
14
Spain
10
Denmark
10
United Kingdom
10
Brazil
7

Who runs them

National Institute of Allergy and Infectious Diseases (NIAID) (15) · Medicago (12) · Gilead Sciences (9) · BioNTech SE (4) · Pfizer (3) · Imperial College London (2) · Assistance Publique - Hôpitaux de Paris (2) · Emergent BioSolutions (2)

What is being tested here

Drugs under test in RNA Virus Infections studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

DrugOpenPhase 3All
BNT162 Vaccine214
Ibuzatrelvir222
Remdesivir133
Dexamethasone111
Acetylcysteine111
Baricitinib111
Bamlanivimab033
Aviptadil022
Amubarvimab022
Romlusevimab022

Coming up

4phase 3 studies under way
7studies finish main data collection within a year3 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

All 7, phase 3 first

Who these studies take

Of the 5 RNA Virus Infections studies recruiting now, 3 (60%) set no upper age limit and 2 (40%) stop at 75 or younger. 2 (40%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 3 (60%) take healthy volunteers.

Recruiting studies that take each age, of 5
AgeWomenMen
101 (20%)1 (20%)
184 (80%)4 (80%)
304 (80%)4 (80%)
405 (100%)5 (100%)
505 (100%)5 (100%)
653 (60%)3 (60%)
753 (60%)3 (60%)
853 (60%)3 (60%)

Across all 98 studies, recruiting or not: 37% stop at 75 or younger and 31% at 65; 13% take children; 0% are for women only and 2% for men only; 43% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long RNA Virus Infections studies take

Of 22 phase 3 interventional studies under RNA Virus Infections, half reached primary completion within 11 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Phase 210 mo5–11 · 11 studies——
Phase 311 mo7–16 · 22 studies——

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

Studies

Recruiting first, then most recently updated. Showing 50 of 98. Browse all 98 → or search them.